

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 319 416 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
18.06.2003 Bulletin 2003/25

(51) Int Cl.7: **A61L 31/16**, A61L 31/08

(21) Application number: 01129570.6

(22) Date of filing: 12.12.2001

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

• Kovacs, Adalbert  
D-69214 Eppelheim (DE)  
• Wolf, Gerhard Karl  
D-69120 Heidelberg (DE)

(71) Applicant: Hehrlein, Christoph, Dr.  
79104 Freiburg (DE)

(74) Representative: KOHLER SCHMID + PARTNER  
Patentanwälte GbR,  
Ruppmannstrasse 27  
70565 Stuttgart (DE)


(72) Inventors:  
• Hehrlein, Christoph  
D-79104 Freiburg (DE)

(54) **Porous metallic stent with a ceramic coating**

(57) The invention described herein consists of a porous metallic stent and methods for producing such a stent using the same to prevent restenosis after angioplasty or the progression of atherosclerosis. The pores

of the metallic stent are created by electrochemically induced pitting. Additional stent coatings are applied to improve stability of the stent, and to modify the release kinetics of a pharmacologically active agent or drug eluting from the stent.

**Fig. 1**



**EP 1 319 416 A1**

## Description

### Field of the Invention

**[0001]** This invention relates to porous metallic stents and methods for producing such stents being capable to incorporate and elute pharmacologically active agents. The purpose of these stents is to prevent restenosis after angioplasty.

### Background of the Invention

**[0002]** A percutaneous transluminal angioplasty (PTA) of blood vessels and more specifically the angioplasty of coronary arteries (PTCA) is a very popular method to eliminate narrowing or stenosis that obstruct blood flow to human organs. Endovascular stents are used as scaffolding devices to prevent abrupt closure of arteries undergoing angioplasty. Stents are also capable of reducing restenosis rates compared with conventional balloon angioplasty. However, restenosis after stent-implantation remains a problem with rates of 20-30% in coronary arteries. Restenosis is the result of excessive damage to the vessel wall during stent placement. Excessive neointima formation within the stents is known to be the major component of restenosis. Restenosis rates after stenting appear to be influenced by the stent design as shown by Rogers et al. (Circulation 1995; 91:2995-3001), and the stent material. Holmes et al (J Am Coll Cardiol 1994; 24:525-531) for instance showed that certain polymers used for the production of drug eluting stents coatings do not decrease but even increase neointima formation. In WO 90/13332 and WO 91/12779, stents have been disclosed that are coated with anti-thrombotic and anti-inflammatory drugs to reduce restenosis rates. In WO 99/00071 another method of stent coating is disclosed by which a DNA coated stent is proposed to reduce restenosis rates. One of the promising drugs that appear to effectively reduce restenosis rates is the substance rapamycin (sirolimus). Sousa et al (Circulation 2001; 103:192-195) showed that a rapamycin-eluting stent reduces neointima formation within the stent, and substantially lower restenosis rates in patients. However, alternative cell-cycle inhibitors may also be effective drugs eluting from stents to prevent restenosis. For instance, US 6200985 disclosed rapamycin derivatives that are lowering restenosis rates after angioplasty administered orally. Calcium channel blockers and angiotensin converting enzyme inhibitors did not reduce restenosis rates when administered systemically. However, high concentrations of these drugs acting locally at the site of angioplasty by eluting from a stent may be alternatives to rapamycin eluting stents. Recently, Brown et al (NEJM 2001; 345: 1583) have shown the combination of simvastatin and niacin reduce cardiovascular events when administered orally. In addition, several antibiotics are considered for prevention of progression of atherosclerosis in coronary artery dis-

ease.

### Summary of the Invention

**[0003]** Porous surfaces have long been known a potential reservoir for liquid drugs. The invention describes porous metallic stents capable of incorporating and eluting drugs. Methods are disclosed for producing a porous metallic stent via processes of pitting. Furthermore, methods are disclosed for producing a polymer coating or ceramic coating of the porous metallic stent via techniques of spotted film deposition. The invention described herein discloses a distinct surface modification of a metallic stent to allow a sustained drug release at various intensities from the stent. However, highly porous metallic stent surfaces may contribute to adhesion of platelets and fibrin, for instance after complete elution of a incorporated drug, and may have disadvantages in the preservation of vessel patency. In addition, highly porous metallic stents need to be stabilised with coatings to reduce the risk of cracks and fissures, or the breaking of stent struts. In the invention described herein, methods of making a porous metallic stent are followed by processes to stabilise the porous stent platform to maintain stent stability, flexibility and ease of deployment. One method described herein is designed to improve biocompatibility of a porous stent by applying a ceramic surface coating onto the porous stent surface. Ceramic coating for surgical instruments have been disclosed in WO98/45225 to form a hardened surface with improve gripping ability of the instruments. WO 00/43572 discloses non-porous ceramic layers for the protection of metallic surfaces. Polymer coatings of metallic stents have become known as reservoirs for pharmacologically active agents. According to Sousa et al (Circulation 2001), drugs eluting from endovascular stents covered with thin polymer films appear to be useful instruments to prevent restenosis after angioplasty in coronary arteries. The methods described herein differ from previous ones by disclosing ways of polymer spot coating of a metallic stent surface. In addition to a ceramic stent coating of highly porous stent, this invention consists of the polymer coating of the pores leaving the remainder of the metallic surface non-coated. The methods disclosed herein provide a cost effective means of producing endovascular stents with the capacity of incorporating high quantities of drugs for sustained drug release. The methods described herein included an introduction of polymers into the microholes of a porous stent. The pores are filled with one or multiple polymers incorporating pharmacologically active agents that are released over time.

**[0004]** Galvele JR (In: treatise on material science and technology, vol.23, ed. Scully JC, Academic Press 1983, London, pp1-53) described a process of electrochemically induced pitting of metals in a textbook of material science. Jessensky et al (Appl Phys Let 1998; 72: 1173) reported on electrochemically induced pore ar-

rays in aluminium-foils. One method disclosed herein used to produce a porous metallic stent consists of a controlled pitting process using aqueous salt solutions. The solutions may create holes in the surface of a metallic stent at sizes between 500 nm to 50  $\mu\text{m}$ . A variation of the incubation period of the stent with the solution modifies the size of the pores. The variation in fluid characteristics of the solution composition enables the production of holes with different configuration (i.e. more or less shallow, ragged or smoothly edged etc). Highly porous structures enable the intake of great amounts of drugs. The eluting capacity of a pharmacologically active agent incorporated into a stent depends on factors binding the agent to the stent. For instance, polymers attached to a metallic stent may prolong the release kinetics of the pharmacologically active agent. A stent may be coated in part with a polymer, and remains partly uncoated to increase the release kinetics around the uncoated part of the stent. Thus, certain areas of the stents may release the agent faster than others depending on the local coating characteristics. However, the mechanical properties of the stent are also affected by increased porosity. In accordance with the present invention, stent made porous by pitting are further treated with a non-porous or nano-porous films of ceramic material such as titanium dioxide or other ceramics to increase stent stability. Examples of biocompatible ceramic coatings include but are not limited to  $\text{TiO}_2$ ,  $\text{ZrO}_2$  or  $\text{Al}_2\text{O}_3$ . Wang et al (Surface Coatings Technol 2000; 128-129: 36) for instance reported that titanium oxide films improve the blood biocompatibility of heart valves.

Example 1: Electrochemically induced pitting under controlled conditions provides a suitable method for porous surface of various metallic stents. Metallic stents made from stainless steel, tantalum, or nitinol are suitable. The electrolyte composition, the applied potential, and the reaction time are important factors that modulate the degree and the morphology of pitting. Stents made from stainless steel 316L for instance are used as working electrodes and are connected with a platinum electrode. The platinum electrode is kept in a slightly acidic NaCl solution at room temperature. A potential of 100 mV is applied, and increased in steps of 0.1 mV/s until 300 mV is reached. By varying the reaction time, different pore sizes can be obtained. Thereafter, the stent is removed, rinsed with distilled water and dried. Prior to electrochemically induced pitting, the metallic stent may be wrapped into microporous foil, which is removed after the pitting process.

Example 2: Metallic stents made porous by the pitting process described in example one are placed into a vacuum chamber. Ceramic material such as titanium dioxide evaporates, and is deposited onto the stent surface by means of argon ion assistance. The energy of the ions may range from 1 to 30 keV.

The i/A-ratio (amount of arriving ions/amount of arriving atoms) may vary from 0.01 to 0.1. The thickness of the titanium dioxide layer is controlled to be in the range of 0.5 - 1 microns. Thereafter, the stent is dipped into a liquid solution of a pharmaceutical agent for stent-based drug release. The microfoil may be removed either before or after the film deposition resulting in entirely coated stents or partly coated ones, depending on the location of the foil.

Example 3: Metallic stents made porous by the pitting process described in example one are dipped into a liquid solvent of a polymer material. After the solvent is removed by evaporation, the polymer outside the holes will be detached chemically. The chemical detachment process for the polymer is performed by using other suitable solvents such as  $\text{CHCl}_3$ . Alternatively, a micro-foil is applied to the stent surface. By these chemical or mechanical processes, the polymer remain inside the pores and is not present on the surface of the stent. The polymer inside the pores stabilises the structure of the stent. Furthermore, the polymer inside the pores of the metallic stent is able to uptake and store liquid solutions. The porous stent is dipped into a liquid solution of a drug or a pharmaceutical agent. The polymer filled pores serve as a reservoir for the pharmacologically active agent and allow sustained release of the agent.

#### Description of Drawings

[0005] Figure 1 shows a cross-sectional view of a porous metallic stent strut 1 with a ceramic coating. The pores 2 of the stent surface 3 are coated with a thin ceramic layer 4. The metallic part of the stent 1 is entirely covered with the ceramic thin film layer 4. A pharmacologically active agent 5 is present in the coated pores 2 of the stent 1.

[0006] Figure 2 shows a cross-sectional view of a porous metallic stent strut 1 with a ceramic coating. The pores 2 of the stent surface 3 are coated with a thin ceramic layer 4. The metallic part of the stent 1 is entirely covered with the ceramic thin film layer 4. The coated pores 2 are filled with a polymer material 6 located on the base of the pores 2 of the stent 1. The polymer material 6 is loaded with a pharmacologically active agent 5.

[0007] Figure 3 shows a cross-sectional view of a porous metallic stent strut 1 with the pores 2 in the stent surface 3. The pores 2 are filled with a polymer material 6 located on the base of the pores 2 of the stent 1. The polymer material 6 is loaded with a pharmacologically active agent 5. The surface 3 of the stent strut 1 is not covered with the polymer material 6.


[0008] The invention described herein consists of a porous metallic stent and methods for producing such a stent using the same to prevent restenosis after angi-

oplasty or the progression of atherosclerosis. The pores of the metallic stent are created by electrochemically induced pitting. Additional stent coatings are applied to improve stability of the stent, and to modify the release kinetics of a pharmacologically active agent or drug eluting from the stent.


## Claims

1. A porous metallic stent (1) coated with a ceramic layer (4), wherein the pores (2) of the stent (1) have the capacity to incorporate and elute pharmacologically active agents (5).
2. The porous metallic stent of Claim 1, wherein the ends of the stent (1) are porous and the middle of the stent (1) is non-porous.
3. The porous metallic stent of claim 1 or 2, wherein the ceramic layer (4) is non-porous.
4. The porous metallic stent of claim 3, wherein a polymer material (6) is located inside the pores (2) of the stent (1).
5. The porous metallic stent of claim 1 or 2, wherein the porous metallic stent (1) is micro-porous and the ceramic layer (4) is nano-porous and wherein the pharmacologically active agent (5) is located in the micro-pores (2) of the porous metallic stent (1) and in the nano-pores of the ceramic layer (4).
6. The porous metallic stent of claim 5, wherein a polymer material (6) is located inside the micro-pores (2) of the porous metallic stent (1).
7. The porous metallic stent of any one of the preceding claims, wherein the ceramic layer (4) consists of either titaniumdioxide ( $\text{TiO}_2$ ), zirconiumdioxide ( $\text{ZrO}_2$ ) or aluminiumoxide ( $\text{Al}_2\text{O}_3$ ).
8. A porous metallic stent (1) containing a polymer material (6) inside the pores (2) of the stent (1) with the capacity to incorporate and elute pharmacologically active agents (5).
9. The porous metallic stent of claim 8, wherein the pores (2) in the stent middle are filled with the polymer material (6) and wherein the pores at the stent ends are not filled with the polymer material (6).
10. The porous metallic stent of any one of the preceding claims, wherein the pharmacologically active agent (5) incorporated and eluting from the stent (1) is one of the group of calcium channel blockers (such as verapamil), one of the group of angiotensin converting enzyme inhibitors (such as captopril), one of the group of statins (such as simvastatin), one of the group of immunosuppressants (such as 32 deoxo-rapamycin), or one of the group of antibiotics (such as erythromycin).
11. A method for producing a porous metallic stent (1), wherein pitting of the metallic stent (1) is electrochemically induced in an inorganic salt solution applying a pitting potential and different reaction times.
12. The method of Claim 11, wherein the porous stent (1) is further coated by an argon beam assisted film deposition of ceramic layer (4).
13. The method of Claim 11 or 12, wherein the pores (2) of the stent (1) are impregnated with biostable polymer material (6) such as polyethylene, polyethylene oxide, polyethylene teraphthalate, ethylene vinyl acetate or silicone.
14. The method of any one of Claims 11 - 13, wherein the pores (2) of the stent (1) are impregnated with biodegradable polymer material (6) such as poly  $\epsilon$ -caprolactone (PCL), poly-D,L-lactid acid (DL-PLA), poly-lactide-co-glycolide, poly- $\beta$ -hydroxybutyrate (PHB), poly-p-dioxanone (PDS), polyorthoester, cyanoacrylates, aliphatic polycarbonates, polyalkylene oxalates, polyiminocarbonates, polyphosphazenes.


**Fig. 1**



**Fig. 2**



**Fig. 3**





European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 01 12 9570

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (InLCI.7)
A	US 5 649 951 A (DAVIDSON JAMES A) 22 July 1997 (1997-07-22) * claims 1,2,6 *	1-14	A61L31/16 A61L31/08
A	EP 0 875 217 A (ADVANCED CARDIOVASCULAR SYSTEM) 4 November 1998 (1998-11-04) * column 2, line 29 - column 3, line 10 *	1-14	
A	WO 01 17577 A (ADVANCED CARDIOVASCULAR SYSTEM) 15 March 2001 (2001-03-15) * page 5, line 15 - page 7, line 21 * * claims 1,7,13,16,18 *	1-14	
A	EP 0 895 761 A (SCHNEIDER USA INC) 10 February 1999 (1999-02-10) * claims 1-3 *	1-14	
			TECHNICAL FIELDS SEARCHED (InLCI.7)
			A61L
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>7 May 2002</b>	Examiner <b>Heck, G</b>
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03 02 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 12 9570

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-05-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5649951	A	22-07-1997	US 5496359 A	05-03-1996
			US 5282850 A	01-02-1994
			US 5258022 A	02-11-1993
			US 5152794 A	06-10-1992
			US 5037438 A	06-08-1991
			US 5549667 A	27-08-1996
			US 5588443 A	31-12-1996
			US 5632779 A	27-05-1997
			US 5611347 A	18-03-1997
			US 5647858 A	15-07-1997
			US 5628790 A	13-05-1997
			AU 675450 B2	06-02-1997
			AU 4786293 A	14-02-1994
			CA 2141183 A1	03-02-1994
			EP 0746266 A1	11-12-1996
			JP 8501953 T	05-03-1996
			WO 9402083 A1	03-02-1994
			AU 660893 B2	06-07-1995
			AU 3217593 A	05-08-1993
			CA 2088696 A1	05-08-1993
			EP 0555038 A1	11-08-1993
			JP 5269192 A	19-10-1993
			AU 639468 B2	29-07-1993
			AU 5980790 A	31-01-1991
			DE 69005219 D1	27-01-1994
			DK 410711 T3	11-04-1994
			EP 0410711 A1	30-01-1991
			ES 2048435 T3	16-03-1994
			JP 2998761 B2	11-01-2000
			JP 4144555 A	19-05-1992
			CA 2021814 A1	26-01-1991
			US 5370694 A	06-12-1994
			US 5180394 A	19-01-1993
			ZA 9005844 A	29-05-1991
EP 0875217	A	04-11-1998	US 6240616 B1	05-06-2001
			CA 2234787 A1	15-10-1998
			EP 0875217 A2	04-11-1998
			JP 10295824 A	10-11-1998
			US 2001013166 A1	16-08-2001
WO 0117577	A	15-03-2001	US 6287628 B1	11-09-2001
			AU 6941800 A	10-04-2001
			WO 0117577 A1	15-03-2001
EP 0895761	A	10-02-1999	US 5899935 A	04-05-1999

EPO FORM P0159

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82



ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 01 12 9570

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-05-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0895761 A	EP	0895761 A2	10-02-1999
	US	6249952 B1	26-06-2001
<hr/>			

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USE)